DUBLIN--(BUSINESS WIRE)--The "Colorectal Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
The Global Colorectal Cancer market accounted for $9.22 billion in 2017 and is expected to reach $13.01 billion by 2026 growing at a CAGR of 3.9% during the forecast period.
Introduction of new and improved therapies and drugs, the rising uptake of higher-priced branded therapies, and several initiatives by governments and private organizations are some of the factors fuelling the market growth. However, factors such as the reluctance toward colorectal cancer medications on the part of patients and a lack of awareness in many parts of the world will pose a threat to the growth of the overall market.
Based on therapies & drugs, the increasing awareness for treating colorectal cancer by chemotherapy and immunotherapy propels the industry growth during the forecast period.
By Geography, North America is a key region in the market and estimated to have a lucrative growth in terms of demand and revenue. This market is fueled by a number of factors, the primary one being greater prevalence of colorectal cancer.
Some of the key players profiled in the Colorectal Cancer market include Abbott Laboratories, Amgen, Clinical Genomics, EDP Biotech, Epigenomics, Hoffmann-La Roche, Novigenix, Quest Diagnostics, Sanofi, Siemens Healthineers and VolitionRX.
What the report offers:
- Market share assessments for the regional and country level segments
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Key Topics Covered
1 Executive Summary
2 Preface
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario
4 Porters Five Force Analysis
5 Global Colorectal Cancer Market, By Therapies & Drugs
5.1 Introduction
5.2 Chemo Therapy
5.2.1 Alkylating Agent - Oxaliplatin (Eloxatin)
5.2.2 Antimetabolites
5.2.2.1 Capecitabine (Xeloda)
5.2.2.2 Fluorouracil (Adrucil)
5.3 Immuno Therapy
5.3.1 Biologic Response Modifiers
5.3.2 Colony-Stimulating Factors
5.3.3 Monoclonal Antibodies
5.3.3.1 Bevacizumab (Avastin)
5.3.3.2 Cetuximab (Erbitux)
5.3.3.3 Panitumumab (Vectibix)
5.3.4 Tumor Vaccines
5.4 Radiation Therapy
5.5 Surgery
5.6 Others Therapies & Drugs
6 Global Colorectal Cancer Market, By Testing & Diagnosis
6.1 Introduction
6.2 Immunochemistry
6.3 Macroscopy
6.4 Microscopy
6.5 Staging
6.6 Tumor Budding
7 Global Colorectal Cancer Market, By Procedure
7.1 Introduction
7.2 Biopsy
7.3 Colostomy
7.4 Magnetic Resonance Imaging (MRI)
7.5 Mammography
7.6 Sigmoidoscopy
8 Global Colorectal Cancer Market, By Product
8.1 Introduction
8.2 Flow Cytometry
8.3 In Situ Hybridization
8.4 Microarrays
8.5 Next-Generation Sequencing
8.6 Targeted Therapy
9 Global Colorectal Cancer Market, By Application
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Other Applications
10 Global Colorectal Cancer Market, By Geography
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 South-America
10.6 Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Abbott Laboratories
12.2 Amgen Inc.
12.3 Clinical Genomics
12.4 EDP Biotech
12.5 Epigenomics AG
12.6 Hoffmann-La Roche AG
12.7 Novigenix S.A.
12.8 Quest Diagnostics
12.9 Sanofi S.A.
12.10 Siemens Healthineers
12.11 VolitionRX
For more information about this report visit https://www.researchandmarkets.com/r/8pmjx8
